Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma,Leukemia

当前位置： X-MOL 学术 › Leukemia › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
Leukemia ( IF 11.4 ) Pub Date : 2017-11-16 , DOI: 10.1038/leu.2017.327
S Bringhen , M D'Agostino , L De Paoli , V Montefusco , A M Liberati , P Galieni , S Grammatico , V E Muccio , F Esma , C De Angelis , P Musto , S Ballanti , M Offidani , M T Petrucci , G Gaidano , P Corradini , A Palumbo , P Sonneveld , M Boccadoro

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma, Published online: 16 November 2017; doi:10.1038/leu.2017.327

中文翻译：